V. Hébert

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 586 citations

Ritux 3, Pharmacology, Pharmacotherapy +2

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 91 citations · Full text

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Marthe Plaquevent, F. Tétart, L. Fardet et al. · Journal of Investigative Dermatology · 2018 · 83 citations · Full text

French General Population, Higher Frequency, Bullous Pemphigoid Patients +2

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

C. Mignard, Maud Maho‐Vaillant, Marie-Laure Golinski et al. · JAMA Dermatology · 2020 · 68 citations · Full text

Risk factors for treatment failure in scabies: a cohort study

Audrey Aussy, Estelle Houivet, V. Hébert et al. · British Journal of Dermatology · 2018 · 59 citations